Table 2 Clinical characteristics of organ donors
Donors n = 35 | |
|---|---|
Severity scores at admission | |
APACHE II | 29 (23–33) |
SOFA | 7 (5–9) |
Donation type | |
Brain-death | 19 (54) |
Maastricht III | 16 (45) |
Pharmacological treatments during ICU | |
Systemic corticosteroids | 12 (34) |
Neuromuscular blockers | 12 (34) |
Days on neuromuscular blockers | 1 (1–2) |
Benzodiazepines | 24 (68) |
Days on benzodiazepines | 1 (0–3) |
Opioids | 26 (74) |
Days on opioids | 2 (0–3) |
Insulin | 12 (34) |
Subcutaneous | 31 (88) |
Intravenous | 3 (8) |
Norepinephrine | 27 (77) |
Maximal dose, µg/kg/min | 0.3 (0.2–0.6) |
Dobutamine | 4 (11) |
Maximum dose, µg/kg/min | 7 (1–16) |
Enteral nutrition | 18 (51) |
Days on enteral nutrition | 2 (0–6) |
Enrolled on a physical therapy program | 4 (11) |
Complications during ICU stay | |
Hyperglycemias > 200 mg/dl | 17 (48) |
Infectious | 12 (34) |
Non-infectious | 6 (17) |
Ventilator settings | |
Controlled modalities | 35 (100) |
PEEP, cmH2O | 7 (6–8) |
Analytical variables on day of inclusion | |
C-reactive protein, mg/dl | 2 (0–17) |
Troponin, ng/l | 41 (8–485) |
Creatine kinase, U/L | 179 (54–581) |
Albumin g/dl | 3 (0.5) |
ICU evolution data | |
Days on mechanical ventilation | 5 (2–9) |
ICU length of stay | 5 (2–9) |